LOS ANGELES--(BUSINESS WIRE)--Sept. 20, 2006--CytRx Corporation (Nasdaq:CYTR) today announced that initial findings from data analysis of the Company’s Phase IIa clinical trial with arimoclomol for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease) will be presented by President and CEO Steven A. Kriegsman and Senior Vice President of Drug Development, Jack Barber, Ph.D., at the UBS Global Life Sciences Conference. The Company’s presentation is scheduled for Tuesday, September 26, 2006 at 9:30 a.m. Eastern time (6:30 a.m. Pacific time) at the Grand Hyatt New York Hotel in New York City.
